1. Catalog
  2. LQCL2308 - CMLE - ARGATROBAN, BIVALIRUDIN, DABIGAT ...
Image For Activity Cover
LQCL2308 - CMLE - ARGATROBAN, BIVALIRUDIN, DABIGATRAN, AND OTHER NOVEL ANTICOAGULANTS IN THE COAGULATION LABORATORY
Course Description

LabQ 2023 Clinical Laboratory: Hematology  

Faculty/Authors

ELIZABETH M. VAN COTT, MD
MASSACHUSETTS GENERAL HOSPITAL
Boston, Massachusetts 

CMLE Credit: 2.0
Estimated Completion Time: 2 hour
Format: Online Educational Activity and Post Exam

Instructions

To claim CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Course to view an overview of the modules in this course.
  3. Click Access to begin the course.
  4. Review the Educational Activity.
  5. Complete and submit the Post Exam.
  6. Submit the course Evaluation to register your credit.

Faculty Disclosures​
The faculty have no relevant financial relationships with commercial interests to disclose.

Technical Considerations

Release Date: 05/27/2023
Review Date:
Expiration Date: 12/31/2025

Course Objectives
Following completion of this activity, you will be able to:

  • discuss the new anticoagulants and which factor each inhibits to produce anticoagulant effects;  

  • describe how the laboratory can determine if these anticoagulants are present in a blood specimen;  

  • describe the hypercoagulation tests that are adversely affected by the new anticoagulants; and 

  • explain how to monitor warfarin while transitioning from argatroban (or dabigatran or bivalirudin) to warfarin.

Summary
Availability: On-Demand
Credit Offered:
2 CMLE Credits
Powered By